FI3694526T3 - Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten - Google Patents

Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten Download PDF

Info

Publication number
FI3694526T3
FI3694526T3 FIEP18865483.4T FI18865483T FI3694526T3 FI 3694526 T3 FI3694526 T3 FI 3694526T3 FI 18865483 T FI18865483 T FI 18865483T FI 3694526 T3 FI3694526 T3 FI 3694526T3
Authority
FI
Finland
Prior art keywords
cystic fibrosis
patient
agnostic
genotype
rescue
Prior art date
Application number
FIEP18865483.4T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Martin D Burke
Katrina A Muraglia
Rajeev S Chorghade
Michael J Welsh
Original Assignee
Univ Illinois
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Univ Iowa Res Found filed Critical Univ Illinois
Application granted granted Critical
Publication of FI3694526T3 publication Critical patent/FI3694526T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP18865483.4T 2017-10-11 2018-10-11 Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten FI3694526T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570795P 2017-10-11 2017-10-11
PCT/US2018/055435 WO2019075214A2 (en) 2017-10-11 2018-10-11 INDEPENDENT RESCUEING OF THE GENOTYPE OF CYSTIC FIBROSIS WITH BICARBONATE CHANNELS WITH SMALL MOLECULES

Publications (1)

Publication Number Publication Date
FI3694526T3 true FI3694526T3 (fi) 2025-02-06

Family

ID=66100102

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18865483.4T FI3694526T3 (fi) 2017-10-11 2018-10-11 Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten

Country Status (10)

Country Link
US (3) US12090164B2 (cg-RX-API-DMAC7.html)
EP (1) EP3694526B1 (cg-RX-API-DMAC7.html)
JP (2) JP7355335B2 (cg-RX-API-DMAC7.html)
AU (2) AU2018348214C1 (cg-RX-API-DMAC7.html)
CA (1) CA3076246A1 (cg-RX-API-DMAC7.html)
DK (1) DK3694526T3 (cg-RX-API-DMAC7.html)
ES (1) ES3009563T3 (cg-RX-API-DMAC7.html)
FI (1) FI3694526T3 (cg-RX-API-DMAC7.html)
PT (1) PT3694526T (cg-RX-API-DMAC7.html)
WO (1) WO2019075214A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018348214C1 (en) 2017-10-11 2025-01-30 The Board Of Trustees Of The University Of Illinois Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels
EP4496588A1 (en) 2022-03-21 2025-01-29 The Board Of Trustees Of The University Of Illinois Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin b
TW202519239A (zh) * 2023-07-19 2025-05-16 美國伊利諾大學理事會 利用遺失蛋白質（ｍｉｓｓｉｎｇ ｐｒｏｔｅｉｎｓ）之小分子模擬物恢復生理機能
WO2025064626A1 (en) * 2023-09-20 2025-03-27 The Board Of Trustees Of The University Of Illinois Additive effects for molecular prosthetcs and cftr modulators in cf epithelia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
KR101424980B1 (ko) * 2002-10-29 2014-08-01 인스메드 인코포레이티드 항감염제의 지속적인 방출
TWI249408B (en) 2003-12-10 2006-02-21 Ind Tech Res Inst New antifungal formulation and manufacturing method thereof
WO2005120460A1 (en) 2004-06-11 2005-12-22 Jitendra Nath Verma Sterol enriched mixed lammelarity amphotericin intercalating liposomes in saline and the process for their preparation
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AU2015343245B2 (en) 2014-11-04 2021-04-22 The Board Of Trustees Of The University Of Illinois Restoring physiology with small molecule mimics of missing proteins
WO2017177228A1 (en) * 2016-04-08 2017-10-12 The Board Of Trustees Of The University Of Illinois Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
AU2018348214C1 (en) 2017-10-11 2025-01-30 The Board Of Trustees Of The University Of Illinois Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels

Also Published As

Publication number Publication date
ES3009563T3 (en) 2025-03-27
US20250009775A1 (en) 2025-01-09
AU2018348214C1 (en) 2025-01-30
JP2020536859A (ja) 2020-12-17
WO2019075214A3 (en) 2020-04-02
EP3694526B1 (en) 2024-12-04
US12090164B2 (en) 2024-09-17
AU2018348214B2 (en) 2024-08-08
CA3076246A1 (en) 2019-04-18
AU2018348214A1 (en) 2020-04-23
WO2019075214A2 (en) 2019-04-18
JP2023126932A (ja) 2023-09-12
EP3694526A2 (en) 2020-08-19
US20250000886A1 (en) 2025-01-02
AU2024259758A1 (en) 2024-11-21
DK3694526T3 (da) 2025-02-03
US20200352970A1 (en) 2020-11-12
EP3694526A4 (en) 2021-06-09
JP7355335B2 (ja) 2023-10-03
PT3694526T (pt) 2025-01-20

Similar Documents

Publication Publication Date Title
FI3694526T3 (fi) Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PH12018500765A1 (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
PH12018500088A1 (en) Substituted tricyclics and method of use
WO2019036008A8 (en) Lipids for use in lipid nanoparticle formulations
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
WO2017091767A3 (en) Drug formulations for cancer treatment
PH12012502296B1 (en) Topical formulation for a jak inhibitor
EP4599848A3 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MY194313A (en) Substituted chromanes and method of use
WO2015151079A3 (en) Auristatin analogues and their conjugates with cell-binding molecules
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
MX2021002042A (es) Inhibidores de arginasa y sus metodos de uso.